US FDA consults on fulfilling obligations for device post-market surveillance studies
This article was originally published in Clinica
Executive Summary
The US FDA is seeking feedback on a draft guideline that explains how medical device manufacturers can fulfil requirements relating to post-market surveillance studies ordered under Section 522 of the Federal Food, Drug and Cosmetic Act.